Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
Author:
Affiliation:
1. QuantPharm LLC North Potomac Maryland USA
2. Roche Innovation Center Basel Basel Switzerland
Publisher
Wiley
Subject
Pharmacology (medical),Modelling and Simulation
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12665
Reference39 articles.
1. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
2. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
3. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
4. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
5. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20;Clinical and Translational Science;2024-04
2. Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence;Kidney International Reports;2024-01
3. Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024
4. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors;Clinical Cancer Research;2023-12-13
5. Time‐dependent clearance can confound exposure–response analysis of therapeutic antibodies: A comprehensive review of the current literature;Clinical and Translational Science;2023-11-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3